Optibiotix signs agreement with Akums

OptiBi­otix Health Plc., a life sci­ences com­pa­ny focused on har­ness­ing the pow­er of human micro­bio­me mod­u­la­tion to tack­le obe­si­ty, high cho­les­terol and dia­betes, has entered into a five-year agree­ment with India’s lead­ing con­tract man­u­fac­tur­er Akums Drugs and Phar­ma­ceu­ti­cals Ltd.
The agree­ment, signed at VitaFoods Europe, held in Gene­va, 15–17 May, grants Akums the rights to exclu­sive­ly man­u­fac­ture and sup­ply prod­ucts con­tain­ing OptiBiotix’s next-gen­er­a­tion pro­bi­ot­ic strain for car­dio­vas­cu­lar health, LPLDL, in India. This is a strate­gic step to add man­u­fac­tur­ing to the sup­ply chain in the Asian pro­bi­ot­ic sup­ple­ments and phar­ma­ceu­ti­cals mar­kets and extends the com­mer­cial reach of LPLDL into South­ern Asia.
Akums is a con­tract man­u­fac­tur­ing organ­i­sa­tion in India and is the man­u­fac­tur­ing part­ner of choice for more than 600 com­pa­nies in the phar­ma­ceu­ti­cal and food sup­ple­ment mar­kets. The com­pa­ny offers more than 3,500 for­mu­la­tions across key health areas, includ­ing car­dio­vas­cu­lar dis­ease, sup­ply­ing more than 12% of all food and drug sup­ple­ments con­sumed in India.